We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $164M
1-Year Est. Return 542.31%
This Fund
S&P 500
This Quarter Est. Return
+19.9%
1 Year Est. Return
+542.31%
3 Year Est. Return
+2,395.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
+$4.56M
Cap. Flow
-$5.88M
Cap. Flow %
-3.58%
Top 10 Hldgs %
74.79%
Holding
56
New
7
Increased
10
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
IMMX icon
Immix Biopharma
IMMX
+$3.2M
2
ADMA icon
ADMA Biologics
ADMA
+$2.28M
3
AVTX icon
Avalo Therapeutics
AVTX
+$2.2M
4
RNTX
Rein Therapeutics
RNTX
+$2.06M
5
CCCC icon
C4 Therapeutics
CCCC
+$1.95M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$4.71M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$3.8M
3
NSPR icon
InspireMD
NSPR
+$2.07M
4
CTMX icon
CytomX Therapeutics
CTMX
+$1.6M
5
VRDN icon
Viridian Therapeutics
VRDN
+$1.31M

Sector Composition

Rank Sector Weight
1 Healthcare 99.39%
2 Miscellaneous 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$9.82B
$29.7M 18.1%
88,781
-12,000
-12% -$3.8M
MPLT
2
MapLight Therapeutics
MPLT
$639M
$17.7M 10.76%
492,893
– –
STRO icon
3
Sutro Biopharma
STRO
$333M
$17M 10.36%
512,160
– –
IMMX icon
4
Immix Biopharma
IMMX
$990M
$11.2M 6.81%
1,085,000
+345,000
+47% +$3.2M
TARA icon
5
Protara Therapeutics
TARA
$233M
$10.9M 6.62%
2,844,652
+10,000
+0.4% +$47.6K
ABVX
6
Abivax
ABVX
$10B
$8.75M 5.33%
65,630
-11,370
-15% -$1.29M
TENX icon
7
Tenax Therapeutics
TENX
$72.6M
$8M 4.87%
549,985
-33,348
-6% -$426K
AVR
8
Anteris Technologies
AVR
$881M
$6.89M 4.2%
700,000
– –
EDSA icon
9
Edesa Biotech
EDSA
$45.6M
$6.73M 4.1%
827,500
– –
EVMN
10
Evommune Inc
EVMN
$445M
$6M 3.65%
451,255
+5,000
+1% +$116K
AVTX icon
11
Avalo Therapeutics
AVTX
$1.03B
$6M 3.65%
324,452
+139,330
+75% +$2.2M
XNCR icon
12
Xencor
XNCR
$1.98B
$4.11M 2.5%
255,000
+5,000
+2% +$62.4K
RZLT icon
13
Rezolute
RZLT
$441M
$3.9M 2.38%
750,000
– –
HRTX icon
14
Heron Therapeutics
HRTX
$65.3M
$3.74M 2.28%
8,753,290
– –
VRCA icon
15
Verrica Pharmaceuticals
VRCA
$91M
$2.89M 1.76%
471,559
– –
CCCC icon
16
C4 Therapeutics
CCCC
$463M
$2.66M 1.62%
+570,000
New +$1.95M
EPRX
17
Eupraxia Pharmaceuticals
EPRX
$555M
$2.33M 1.42%
352,000
– –
ADMA icon
18
ADMA Biologics
ADMA
$2.15B
$2.09M 1.27%
+250,000
New +$2.28M
RNTX
19
Rein Therapeutics
RNTX
$76.7M
$1.77M 1.08%
+1,700,000
New +$2.06M
LYEL icon
20
Lyell Immunopharma
LYEL
$352M
$1.48M 0.9%
105,000
+3,000
+3% +$54.3K
NSRX
21
Nasus Pharma
NSRX
$43.7M
$1.26M 0.77%
359,390
– –
PROF
22
Profound Medical
PROF
$252M
$1.13M 0.69%
170,278
-115,432
-40% -$776K
JSPR icon
23
Jasper Therapeutics
JSPR
$23.6M
$1.12M 0.68%
2,668,395
– –
TENX icon
24
CALL
Tenax Therapeutics
TENX
$72.6M
$1,000K 0.61%
+68,700
New +$878K
PTGX icon
25
Protagonist Therapeutics
PTGX
$9.43B
$454K 0.28%
3,700
– –
1
2 3

Similar funds

WCM
Winebrenner Capital Management Louisville, Kentucky $164M AUM 12.81% 1-Year Est. Return
HWM
Hemming & Wealth Management Traverse City, Michigan $164M AUM
PSIWM
Paradigm Strategies in Wealth Management Maple Grove, Minnesota $164M AUM 18.07% 1-Year Est. Return
JWM
JDH Wealth Management Santa Rosa, California $164M AUM 28.4% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
IFA
Interactive Financial Advisors New Lenox, Illinois $164M AUM 18.28% 1-Year Est. Return
SC
Simcoe Capital Spokane, Washington $164M AUM
FLFS
Family Legacy Financial Solutions Cary, North Carolina $164M AUM 62.92% 1-Year Est. Return

Velan Capital Investment Management's Q2 2026 Portfolio in Review

As of Q2 2026, Velan Capital Investment Management held 56 positions worth $164M, up 2.9% from $160M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Velan Capital Investment Management withdrew a net $5.88M in Q2 2026, closing 5 positions and reducing 11 holdings. Its most notable exit was Esperion Therapeutics, an estimated $4.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Velan Capital Investment Management opened a new position in ADMA Biologics worth $2.09M.

  • Velan Capital Investment Management's largest Q2 2026 buy was ADMA Biologics: 250,000 shares worth $2.09M.
  • Velan Capital Investment Management added most to Immix Biopharma in Q2 2026, an estimated $3.2M increase.
  • Velan Capital Investment Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $3.8M.
  • Velan Capital Investment Management fully exited Esperion Therapeutics in Q2 2026, selling an estimated $4.71M.
  • Velan Capital Investment Management's ten largest holdings make up 75% of its $164M portfolio in Q2 2026.
  • Velan Capital Investment Management opened 7 new positions and closed 5 in Q2 2026.
  • Velan Capital Investment Management's portfolio value rose 2.9% quarter-over-quarter to $164M.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.